Clinical Policy: Kidney Disorders

Inherited kidney disorders and inherited disorders that indirectly affect the kidneys can be more common, such as autosomal dominant polycystic kidney disease, or more rare, such as Lowe syndrome and Fabry disease. Identifying the genetic cause of an inherited kidney disorder can help direct treatment, inform family members, and contribute to the overall understanding of the genetic etiology of chronic kidney disease. More advanced next-generation sequencing, such as exome sequencing and comprehensive genetic testing panels are emerging as a first-line diagnostic method for patients with chronic kidney disease.

Below is a list of higher volume tests and the associated laboratories for each criteria section. This list is not all inclusive.

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Example Tests (Labs)</th>
<th>Criteria Section</th>
<th>Common ICD Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>81403</td>
<td>PKD1 Targeted Mutation Analysis</td>
<td>Targeted Variant Analysis</td>
<td>Q61, N18</td>
</tr>
<tr>
<td></td>
<td>PKD2 Targeted Mutation Analysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PKHD1 Targeted Mutation Analysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>81406,81407, 81479</td>
<td>PKD1 Sequencing Analysis</td>
<td>Simple-gene or Multigene Panel Analysis</td>
<td>Q61, N18</td>
</tr>
<tr>
<td></td>
<td>PKD2 Sequencing Analysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PKHD1 Sequencing Analysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>81404,81405, 81406,81407, 81408, 81479</td>
<td>Autosomal Dominant and Recessive Polycystic Kidney Disease (ADPKD and ARPKD) Panel (PreventionGenetics)</td>
<td>Simple-gene or Multigene Panel Analysis</td>
<td>Q61, N18</td>
</tr>
<tr>
<td>81404,81405, 81406,81407, 81408, 81479</td>
<td>Expanded Polycystic Kidney Disease</td>
<td>Simple-gene or Multigene Panel Analysis</td>
<td>Q61, N18</td>
</tr>
<tr>
<td></td>
<td>NGS Panel (Sequencing &amp; Deletion/Duplication) (Fulgent Genetics)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>81401,81402, 81403,81404, 81405,81406,</td>
<td>RenaSight (Natera)</td>
<td>Comprehensive Kidney Disease Panels</td>
<td>N00-N08, N10-N16, N17-N19, Q61, R31</td>
</tr>
</tbody>
</table>

See Important Reminder at the end of this policy for important regulatory and legal information.
### CPT® Codes | Example Tests (Labs) | Criteria Section | Common ICD Codes |
--- | --- | --- | --- |
81407, 81408, 81479 | KidneySeq Version 4 Comprehensive Testing (Iowa Institute of Human Genetics) Congenital Abnormalities of the Kidney and Urinary Tract (CAKUT) Panel (PreventionGenetics) RenalZoom (DNA Diagnostic Laboratory - Johns Hopkins Hospital) |  |  |
81479 | Allosure Kidney (CareDx, Inc.) Prospera (Natera) | Donor-Derived Cell Free DNA for Kidney Transplant Rejection | T86.11, T86.12, Z94.0 |
0118U | Viracor TRAC dd-cfDNA (Viracor Eurofins) | Donor-Derived Cell Free DNA for Kidney Transplant Rejection | T86.11, T86.12, Z94.0 |
81400-81408 | See list below | Other Kidney Disorders | N/A |

This policy document provides criteria for hereditary kidney disorders. Please refer to:

- **CP.MP.230 Genetic Testing: Multisystem Inherited Disorders, Intellectual Disability, and Developmental Delay** for criteria related to genetic disorders that affect multiple organ systems.

- **CP.MP.225 Genetic Testing: Hereditary Cancer Susceptibility** for criteria related to von Hippel Lindau (VHL) syndrome and other hereditary cancer syndromes.

- **CP.MP.222 Genetic Testing: General Approach to Genetic Testing** for criteria related to genetic testing for kidney disease that is not specifically discussed in this or another nongeneral policy.

**Policy/Criteria**

**Polycystic Kidney Disease**

**Targeted Variant Analysis**

I. It is the policy of health plans affiliated with Centene Corporation® that PKD1, PKD2, GANAB, DNAJB11 or PKHD1 targeted variant analysis (81403) to establish a diagnosis of autosomal dominant polycystic kidney disease is considered **medically necessary** when:
CLINICAL POLICY
Genetic Testing Kidney Disorders

A. The member/enrollee has a close relative with a known pathogenic or likely pathogenic variant in \( PKD1, \ PKD2, \ GANAB, \ DNAJB11, \) or \( PKHD1. \)

II. It is the policy of health plans affiliated with Centene Corporation\(^\text{®} \) that \( PKHD1 \) targeted variant analysis (81403) to establish a diagnosis of autosomal recessive polycystic kidney disease is considered medically necessary when:

A. The member/enrollee has a sibling with known biallelic pathogenic or likely pathogenic variants in \( PKHD1. \)

III. It is the policy of health plans affiliated with Centene Corporation\(^\text{®} \) that current evidence does not support \( PKD1, PKD2, GANAB, DNAJB11, \) or \( PKHD1 \) targeted variant analysis (81403) to establish a diagnosis of autosomal dominant or autosomal recessive polycystic kidney disease for all other indications.

Single Gene or Multigene Panel Analysis

I. It is the policy of health plans affiliated with Centene Corporation\(^\text{®} \) that \( PKD1 \) (81407), \( PKD2 \) (81406), \( GANAB \) (81479), \( DNAJB11 \) (81479), \( PKHD1 \) (81479) sequencing and/or deletion/duplication analysis or multigene panel analysis (81404, 81405, 81406, 81407, 81408, 81479) to confirm or establish a diagnosis of polycystic kidney disease is considered medically necessary when:

A. The member/enrollee has any of the following clinical features of polycystic kidney disease:
   1. Multiple bilateral renal cysts
   2. Cysts in other organs (especially the liver, seminal vesicles, pancreas, and arachnoid membrane)
   3. Hypertension in an individual younger than age 35
   4. Intracranial aneurysm
   5. Bilaterally enlarged and diffusely echogenic kidneys
   6. Poor corticomedullary differentiation
   7. Hepatobiliary abnormalities with progressive portal hypertension
   8. Congenital hepatic fibrosis (CHF) with portal hypertension,

II. It is the policy of health plans affiliated with Centene Corporation\(^\text{®} \) that current evidence does not support \( PKD1 \) (81407), \( PKD2 \) (81406), \( GANAB \) (81479), \( DNAJB11 \) (81479), \( PKHD1 \) (81479) sequencing and/or deletion/duplication analysis or multigene panel analysis (81404, 81405, 81406, 81407, 81408, 81479) to confirm or establish a diagnosis of polycystic kidney disease for all other indications.
Comprehensive Kidney Disease Panels
I. It is the policy of health plans affiliated with Centene Corporation® that genetic testing for kidney disease via a comprehensive kidney disease panel (81401, 81402, 81403, 81404, 81405, 81406, 81407, 81408, 81479) is considered **medically necessary** when meeting all of the following:

   A. The member/enrollee has chronic kidney disease with an undetermined cause after undergoing standard-of-care workup studies (e.g., history and physical examination, biochemical testing, renal imaging, or renal biopsy),

   B. The member/enrollee meets at least one of the following:
      1. Onset of chronic kidney disease under 40 years of age,
      2. One or more first\(^{1a}\)- or second-degree\(^{1b}\) relatives with chronic kidney disease,
      3. Consanguineous family history,

   C. The member/enrollee is being considered for a kidney transplant.

II. It is the policy of health plans affiliated with Centene Corporation® that current evidence does not support genetic testing for kidney disease via a comprehensive kidney disease panel (81401, 81402, 81403, 81404, 81405, 81406, 81407, 81408, 81479) for all other indications.

Donor-Derived Cell-Free DNA For Kidney Transplant Rejection
I. It is the policy of health plans affiliated with Centene Corporation® that current evidence does not support the use of peripheral blood measurement of donor-derived cell-free DNA in the management of patients after renal transplantation(81479, 0118U) (e.g., Allosure Kidney, Viracor TRAC) for all indications, including but not limited to:

   A. Detection of acute renal transplant rejection
   B. Detection of renal transplant graft dysfunction

Other Kidney Disorders
The following is a list of conditions that have a known genetic association. Due to their relative rareness, these genetic tests may be appropriate to establish or confirm a diagnosis.

I. It is the policy of health plans affiliated with Centene Corporation® that genetic testing to establish or confirm one of the following genetic kidney disorders to guide management is considered **medically necessary** when the member/enrollee demonstrates clinical features* consistent with the disorder (the list is not meant to be comprehensive, see II below):

   A. [Alport Syndrome](#)
   B. [C3 Glomerulopathy](#)
C. Congenital nephrotic syndrome
D. Cystinosis
E. Cystinuria
F. Fabry Disease
G. Genetic (familial) atypical hemolytic-uremic syndrome (aHUS)
H. Primary Hyperoxaluria

II. It is the policy of health plans affiliated with Centene Corporation® that genetic testing to establish or confirm the diagnosis of all other kidney disorders not specifically discussed within this or another medical policy will be evaluated by the criteria outlined in CP.MP.222 General Approach to Genetic Testing (see policy for criteria).

*Clinical features for a specific disorder may be outlined in resources such as GeneReviews, OMIM, National Library of Medicine, Genetics Home Reference, or other scholarly source.

Notes and Definitions
1. Close relatives include first, second, and third degree blood relatives on the same side of the family:
   a. **First-degree relatives** are parents, siblings, and children
   b. **Second-degree relatives** are grandparents, aunts, uncles, nieces, nephews, grandchildren, and half siblings
   c. **Third-degree relatives** are great-grandparents, great aunts, great uncles, great grandchildren, and first cousins

Background

Kidney Disease Improving Global Outcomes (KDIGO)
The Kidney Disease Improving Global Outcomes (2009) issued guidelines for the care of kidney transplant recipients. The guidelines included the following recommendations:

- “We recommend kidney allograft biopsy when there is a persistent, unexplained increase in serum creatinine. (1C)”
- “We suggest kidney allograft biopsy when serum creatinine has not returned to baseline after treatment of acute rejection. (2D)”
- “We suggest kidney allograft biopsy every 7-10 days during delayed function. (2C)”
- “We suggest kidney allograft biopsy if expected kidney function is not achieved within the first 1-2 months after transplantation. (2D)”
- “We suggest kidney allograft biopsy when there is new onset of proteinuria. (2C)”
- “We suggest kidney allograft biopsy when there is unexplained proteinuria ≥3.0 g/g creatinine or ≥3.0 g per 24 hours. (2C)”

Renal Association
The Renal Association (2017) published clinical practice guidelines for the care of patients from the period following kidney transplantation until the transplant is no longer working or the patient dies, which included the following:

- Guideline 4.1 – “We recommend that a transplant renal biopsy should be carried out before treating an acute rejection episode unless this will substantially delay treatment or pose a significant risk to the patient (1C)”
- Guideline 4.6 – “We suggest that a serum sample be sent at the time of renal biopsy (for graft dysfunction) to look for human leukocyte antigen (HLA)-specific antibodies (2C)”
- Guideline 5.1 – “We recommend that early identification of graft injury is desirable to maximise the potential for intervention. A proactive and systematic approach should employed to manage graft dysfunction (1C)”
- Guideline 5.2 – “We suggest that renal function should be monitored at each clinic visit by assessment of serum creatinine and qualitative evaluation of urine protein excretion by dipstick, supplemented by spot protein:creatinine ratio (PCR) or albumin:creatinine ratio (ACR) if positive (2C)”
- Guideline 5.3 – “We suggest that renal biopsy is the optimal investigation for parenchymal causes of graft dysfunction where the cause is uncertain (2C)”

**Coding Implications**

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2021, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Revision Date</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy developed.</td>
<td>02/22</td>
<td>02/22</td>
</tr>
</tbody>
</table>

**References**


**Clinical Policy**

**Genetic Testing Kidney Disorders**


**Important Reminder**
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.
Genetic Testing Kidney Disorders

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of member/enrollees. This clinical policy is not intended to recommend treatment for member/enrollees. Member/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, member/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, member/enrollees and their representatives agree to be bound by such terms and conditions by providing services to member/enrollees and/or submitting claims for payment for such services.

Note: For Medicaid member/enrollees, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

Note: For Medicare member/enrollees, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at http://www.cms.gov for additional information.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.